MP
Mind Pharmaceuticals is a clinical asset stage company developing novel therapeutics for central nervous system disorders, initially targeting Treatment Resistant Depression. The lead candidate, MIND001, is an intravenous formulation of DMT designed for rapid onset and sustained efficacy with a short treatment duration. This approach aims to provide an effective alternative to daily dosing regimens required by conventional antidepressants.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Mind Pharmaceuticals is a clinical asset stage company developing novel therapeutics for central nervous system disorders, initially targeting Treatment Resistant Depression. The lead candidate, MIND001, is an intravenous formulation of DMT designed for rapid onset and sustained efficacy with a short treatment duration. This approach aims to provide an effective alternative to daily dosing regimens required by conventional antidepressants.